Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Inizio Unveils Next-Generation Hub Services at Asembia 2026, Setting a New Standard in Patient Access

May 5, 2026 |  

Integrated capabilities combining advanced analytics, pharmacy, and specialized talent to improve access, affordability, and adherence

- PMLiVE

Inizio announced the official launch of its fully integrated, end-to-end Hub Services, a cornerstone of its market-leading Patient Solutions offering. Delivered by Inizio Engage, the Inizio business unit specializing in patient engagement and support, this next-generation solution addresses the growing complexity of patient access, reimbursement, and adherence, while enabling clients to partner with a more agile, strategic, and outcome-driven organization.

As life sciences organizations navigate an increasingly dynamic policy and payer landscape, and higher expectations from patients, the need for more connected, patient-centric support models has never been greater. “Inizio Engage’s evolved Hub Services introduces a next-generation approach, integrating human expertise, intelligent technology, and pharmacy capabilities, supported by advanced analytics to simplify and accelerate the path to therapy,” said Ryan Quigley, CEO, Inizio. “This launch represents another opportunity for Inizio to lead the way as the global Intelligent Commercialization partner, bringing together insight, innovation, and execution to deliver more coordinated, patient-centered solutions for our clients.”

Read full article here. 

This content was provided by Inizio

Company Details

- PMLiVE

Inizio

Email
Website

 Latest Content from  Inizio 

Pegasus shortlisted for ‘Consultancy of the year’ at 2014 Communique Awards

Brighton-based independent healthcare specialist looks to add award to growing list of accolades

Pegasus Moves to Brighton

Top UK Healthcare Communications Consultancy Moves to Brighton

Warehousing of HCV patients reaches new high

A new study conducted by Research Partnership reveals that 90% of physicians treating HCV patients in the US have reported they are now “warehousing” patients (holding off treatment) in expectation...

Brand leaders in RA will lose market share, predict rheumatologists

Rheumatologists believe that the current market for biologic treatments in Rheumatoid Arthritis (RA) will see key changes in the next three years.

Removing the Roadblocks to Effective Patient Treatment

How can pharma benefit from improved patient understanding? Welcome to a new column in which Mary Assimakopoulos, Founding Director of pharma market research specialist the Research Partnership reveals findings from...

Driving Earlier Diagnosis: A Case Study in Psoriatic Arthritis

Following a survey of 1000 Psoriatic Arthritis patients, Mary Assimakopoulos shares some of the root causes behind a late diagnosis of this debilitating illness, and the patients’ own feelings towards...

The Difficulties of Living with Depression Don’t End with the Illness Itself

This month Mary Assimakopoulos examines some of the insights gathered while surveying 2,000 patients suffering with this often misunderstood mental illness.

Patient Power: Too Much of a Good Thing?

Mary Assimakopoulos, reveals findings from the company’s Therapy Watch market research data, investigating patient behaviour in Crohn’s Disease and discusses how pharma can benefit from improved patient understanding

Webinar: Mobile Research in Asia and Emerging Markets

Current statistics around mobile technology reveal that many physicians in Asia are now using smartphones, tablets and other mobile devices to assist them in their daily practices. In China alone,73%...

Webinar: Understanding the Patient Journey in Order to Influence Prescribing Decisions

Using real data, this webinar looks at the increasingly popular view that says we need to understand more about the patient and the relationship they have with their physicians in...